

September 19, 2019

Human Metabolome Technologies, Inc.  
(Stock code: 6090, TSE Mothers)

## **HMT BioMedical® announces the launch of contract research services**

HMT BioMedical, Inc. (“HMT-BM”), a subsidiary of Human Metabolome Technologies, Inc (“HMT”) will commence the following contract research services:

### **1. Exosome purification service**

The exosome purification reagent kit for research use, also known as ExoIntact™ Exosome Isolation Kit (hereinafter referred to as “the product”), was launched on 25 April 2019, and sales have started in Japan and overseas.

Currently, we have expanded the scope of our business and started to offer an exosome purification service using the product in addition to the kit itself. HMT-BM will continue to support exosome research with these additional services. Exosomes are garnering interest as a treasure-trove for biomarker discover by providing high-purity, intact (preserved exosome structures) and high-quality exosomes, utilizing the unique features of the product and through this service HMT-BM aims to harmonize and encourage this field of study.

### **2. Phosphorylethanolamine (PEA) measurement service (for research purposes)**

HMT-BM will start an analytical service for phosphorylethanolamine (PEA) in plasma. PEA is a biomarker<sup>※1</sup> candidate for major depressive disorder (hereinafter referred to as “depression”). HMT-BM has been conducting various studies with PEA holding multiple patents in Japan, the US, Europe and China. As interests in prevention, early detection and treatment of depression continue to soar, we will provide these services for the growing medical need for PEA quantitation from mental health research institutions, pharmaceutical companies and health management organizations by providing a PEA analytical service.



Mr HASHIZUME Katsuhito, CEO of HMT-BM stated “We aspire to contribute to improving mental and physical health of people. I believe that these two new services will help our clients make a significant impact in biomarker discovery and R&D in the mental health area.”

HMT-BM has commenced the above contract services as of 16 September and will further expand its business in the future.

※1 biomarker

A measurable indicator of the severity or presence of a medical condition

#### About Human Metabolome Technologies, Inc. (HMT)

HMT is a biotech venture founded in 2003, based on the research achievements attained at the Institute for Advanced Biosciences (IAB), Keio University, Japan. HMT provides capillary electrophoresis mass spectrometry-based metabolomics services for researchers from companies and public research institutions. HMT is currently working on the development of clinical tests that utilize biomarkers for objective assessment of specific diseases. The company was listed on TSE Mothers in December 2013, on the 10<sup>th</sup> anniversary of its founding.

#### Public Relations Inquiries

Human Metabolome Technologies, Inc.  
Head of IR  
Kenji Sasabe  
TEL 03-3551-2180 FAX 03-3551-2181  
[invre1@humanmetabolome.com](mailto:invre1@humanmetabolome.com)

#### Product-related Inquiries

HMT BioMedical, Inc.  
TEL 045-534-9316 FAX 045-534-9317  
[bm-support@humanmetabolome.com](mailto:bm-support@humanmetabolome.com)